This study is for people with HIV-1 who have never been treated. It tests two new drugs, GS-1720 and GS-4182, to see if they are safe and effective compared to the usual treatment called Biktarvy. GS-1720 is an experimental oral drug that helps block the virus, and GS-4182 is a version of another drug called Lenacapavir. This study has two parts: Phase 2 lasts for 24 weeks, and Phase 3 lasts for 48 weeks. To join, participants must have a certain amount of the virus in their blood and cannot have used certain other HIV drugs before. They also need to have healthy lab results, like enough blood cells and working kidneys and liver.

• The study lasts up to 48 weeks, with regular check-ups.
• Participants may receive new drugs or the standard treatment.
• Eligibility depends on health and previous treatments.